Prognostic value of the immunohistochemical detection of cancer-associated fibroblasts in oral cancer : a systematic review and meta-analysis
Dourado, Mauricio Rocha; Guerra, Eliete N. S.; Salo, Tuula; Lambert, Daniel W.; Coletta, Ricardo D. (2017-09-05)
Dourado MR, Guerra ENS, Salo T, Lambert DW, Coletta RD. Prognostic value of the immunohistochemical detection of cancer‐associated fibroblasts in oral cancer: A systematic review and meta‐analysis. J Oral Pathol Med. 2018;47:443‐453. https://doi.org/10.1111/jop.12623
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. "This is the peer reviewed version of the following article: Dourado MR, Guerra ENS, Salo T, Lambert DW, Coletta RD. Prognostic value of the immunohistochemical detection of cancer‐associated fibroblasts in oral cancer: A systematic review and meta‐analysis. J Oral Pathol Med. 2018;47:443‐453. https://doi.org/10.1111/jop.12623, which has been published in final form at https://doi.org/10.1111/jop.12623. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."
Aim: To perform a meta-analysis to assess whether the presence of cancer-associated fibroblasts (CAF) is a prognostic marker of oral squamous cell carcinomas (OSCC).
Methods: Immunohistochemical studies assessing the prognostic relevance of CAF (alpha smooth muscle actin (α-SMA)-positive fibroblasts) in patients with OSCC were systematically reviewed using Cochrane, Lilacs, PubMed, Scopus, and Web of Science databases. The outcomes assessed were overall survival (OS) and disease-free survival (DFS). The meta-analysis was performed using the random- and fixed-effects model with adjusted hazard ratio (HR) and 95% confidence intervals (95% CI) as effect measures. The methodological quality of the included studies was assessed using the Meta-Analysis of Statistics Assessment and Review Instrument (MAStARI) tool, and the evidence quality was assessed by the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system.
Results: The presence of high levels of CAF in the stroma of OSCC predicted shortened time to DFS (HR = 3.32, 95% CI: 2.09–5.26, P < .00001) and an overall decrease in survival (HR: 2.16, 95% CI: 1.60–2.92, P < .00001). Moreover, high presence of CAF was frequently reported in association with parameters that worsen the prognosis in OSCC, including advanced disease stage (TNM classification), recurrence, tumor grade, depth of invasion, vascular, lymphatic and neural invasion, and extranodal metastatic spread.
Conclusion: The presence of CAF, as assessed by α-SMA-positive fibroblasts in the stroma, indicates poor prognosis in patients with OSCC.
- Avoin saatavuus